News und Analysen
Gilead Sciences: Einfach kein entscheidender Durchbruch!
Die Aktie von Gilead Sciences (WKN: 885823) steht zuletzt, aufgrund der Covid-19-Pandemie, immer wieder im Mittelpunkt des Anlegerinteresses (wir berichteten). So beflügelte die Aktie kürzlich sogar
Agilent Signs Sponsorship Agreement with My Green Lab
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific
Veeva Introduces New Capabilities for Remote Drug Sampling in Veeva CRM Engage Meeting
Veeva Systems (NYSE: VEEV) today introduced new remote sampling capabilities in Veeva CRM Engage Meeting. Remote sampling enables field reps to capture and fulfill healthcare professionals’ (HCPs)
Quidel to Hold First Quarter 2020 Financial Results Conference Call on May 6th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2020 financial
Illumina Makes Software Toolkit Available Free of Charge to Support Worldwide Efforts to Combat COVID-19
Illumina, Inc. (NASDAQ: ILMN) announces the Illumina SARS-CoV-2 Data Toolkit, a new suite of data analysis tools and workflow functionality for researchers working with the virus using
Illumina Reports Preliminary Revenue for First Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2020 and withdrew its 2020 guidance.
Subject to quarter-end closing adjustments, the Company
Agilent Technologies Provides Update on COVID-19 Impact; Sets Second-Quarter Earnings Call for May 21
Agilent Technologies, Inc. (NYSE: A) today announced that due to the expanded and evolving nature of the COVID-19 pandemic and resulting effects on customer operations, it is withdrawing its
Pfizer Advances Battle Against COVID-19 on Multiple Fronts
Pfizer Inc. (NYSE: PFE) today announced important advances in the battle against the global COVID-19 pandemic.
As outlined in Pfizer’s five-point plan, the company has been collaborating across
Pfizer and BioNTech Announce Further Details on Collaboration to Accelerate Global COVID-19 Vaccine Development
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), and Pfizer Inc. (NYSE: PFE) today disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine
Portfoliocheck: Mit United Health spielt Andreas Halvorsen die Gesundheitskarte
U.S. FDA Approves BRAFTOVI® (Encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment
Pfizer to Hold Virtual-Only 2020 Annual Meeting of Shareholders
Pfizer Inc. (NYSE: PFE) today announced that its 2020 Annual Meeting of Shareholders will be held in a virtual-only format due to continued public health concerns related to coronavirus / COVID-19
Veeva Announces Alliances for Digital Field Engagement
Veeva Systems (NYSE:VEEV) today announced industry alliances to accelerate the industrywide shift toward digital engagement. Together with Accenture, Deloitte, and other alliance partners, Veeva is
Pfizer and The Pfizer Foundation Donate $40 Million in Charitable Grants, Expand Product Access and Mobilize Colleagues to Combat COVID-19 Pandemic
Pfizer Inc. (NYSE: PFE) and The Pfizer Foundation today announced the commitment of $40 million in medical and charitable cash grants to help combat the global health effects of the COVID-19
Pfizer Receives European Approval for Oncology Biosimilar, RUXIENCE™ (rituximab)
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved RUXIENCE™ (rituximab), a monoclonal antibody (mAb) and biosimilar to MabThera® (rituximab), for the treatment
Susan Desmond-Hellmann Elected to Pfizer’s Board of Directors
Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Desmond-Hellmann to its Board of Directors, effective immediately. Dr. Desmond-Hellmann, age 62, was also appointed to the
Dexcom Schedules First Quarter 2020 Earnings Release and Conference Call for April 28, 2020 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2020 financial results after market close on Tuesday, April 28, 2020. Management will hold a conference call to
Free Remote Monitoring Solution Now Available for All Clinical Research Sites
Veeva Systems (NYSE: VEEV) today announced new remote monitoring capabilities in Veeva SiteVault Free for source document review and verification in clinical trials. Veeva SiteVault Free gives
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
Merck & Co., Inc., (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Eli Lilly and Company (NYSE: LLY) today announced medical service volunteer programs to enable employees who are licensed medical
Agilent Introduces New Handheld Raw Material ID System for Pharmaceutical Manufacturers
Agilent Technologies Inc. (NYSE: A) today announced the launch of the newest instrument in its Raman technology portfolio. The new Agilent Vaya Raman raw material identity verification system is a
Agilent Technologies to Change Location of Annual Meeting
Agilent Technologies, Inc. (NYSE: A) today filed a supplement to its proxy statement with the Securities and Exchange Commission announcing a change of location for its previously adjourned annual
Agilent Announces New Class 1 Triple Quadrupole LC/MS System
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.
Agilent’s
Pfizer Completes $1.25 Billion Sustainability Bond for Social and Environmental Impact
Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and maturing April 1, 2030. This is Pfizer’s
Humana Works to Increase Capacity for Coronavirus Treatment
To prepare for the influx of patients who will need to be treated for coronavirus (COVID-19), Humana Inc. (NYSE: HUM) is taking steps to make it easier for members and health systems. Specifically
Veeva Data Cloud to Deliver New Approach for Patient and Prescriber Data
Veeva Systems (NYSE: VEEV) today announced Veeva Data Cloud to help support the industry by bringing greater innovation and choice to the data market. Veeva Data Cloud will include longitudinal